NCT01440257

A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria

A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effect of treatment with CCX140-B on urinary albumin excretion in subjects with type 2 diabetes mellitus and albuminuria, as well as to study the safety and efficacy of the medication in this patient population.

Detailed description

Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.

Conditions

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Placebo	Placebo capsules once daily
DRUG	CCX140-B	CCX140-B capsules once daily (Group B)

Timeline

• Start date: 2011-09-01
• Primary completion: 2013-02-01
• Completion: 2013-09-01
• First posted: 2011-09-26
• Last updated: 2025-02-27

Locations

1 site across 1 country: Netherlands